RNA2026 | 6th Small Nucleic Acid Drug Development Conference Held in Suzhou on March 5–6

Compared with traditional small molecule and antibody drugs, small nucleic acids have the disruptive advantages of simple design, precise targets, long-lasting effects, and the ability to target "undruggable" points. By 2025,More than 20 products approved globally, with international giants like Alnylam and Ionis dominating the market through star products such as Onpattro and Spinraza.However, behind the industry's boom lie multiple bottlenecks, such as limitations in indications, insufficient extrahepatic targeting of delivery systems, complex solid-phase synthesis processes, and technical challenges like off-target effects and toxicity control. At the same time, the pressures of international competition and homogenized research and development continue to emerge. The topic of small nucleic acids still deserves our deep reflection and discussion!

The curtain has risen on 2026, and we are about toMarch 5-6InSUZHOUGrandly HostedThe 6th Annual Conference on the Development of Small Nucleic Acid Drugs. As of now, this conference has gatheredInnovent Bio, Salubris, Yuhong Pharmaceutical, Guowei Bio, Xuanjing Bio, R-Pharm, Shian Bio, Sirnaomics, Haichang Biotech, Xianyan Bio, Youjia Bio, Aima Bio, Junli Pharma, Ying Nucleic Acid Bio, Anlong, Brii Biosciences, Tianjin Pharmar, Aioxi Bio, Coenlys, Golos Bio, Vireton, Yuanbio CapitalMore than 30 companies, and the invitations are still ongoing! We look forward to more investment institutions, research scholars, industry leaders, and clinical experts joining in, launching a grand event exclusively for small nucleic acids!